PPGN Share Price Performance
CHF 24.00
-6.40 (-21.05%)
27.5% undervalued intrinsic discount
CHF 33.10
Fair Value
Price CHF 24.00
PKU CHF 33.10
Fair ValueCHF 33.10
Share Pricen/a
PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt
Sep 25
PolyPeptide Group AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
PPGN Community Narratives
PK
PKU·
Fair Value CHF 33.1 27.5% undervalued intrinsic discount
Biotech longerterm bet
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Biotech longerterm bet
211011 Draupnir noch ein Anteil von rund 55,5% an Polypeptide. Der «Free Float» an der Börse SIX erhöht sich dadurch gleichzeitig von 40,0 auf rund 44,5%.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
PK
CHF 33.1
27.5% undervalued intrinsic discount
PKU Fair Value
Revenue growth
11.03% p.a.
Profit Margin
13.61%
Future PE
18.34x
Share price in 2029
CHF 41.08
Snowflake Analysis
PolyPeptide Group AG Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Mar 12, 2026
- -1.05
- 11.26%
- -9.41%
- 27.3%
About PPGN
- Founded
- 1952
- Employees
- 1400
- CEO
- WebsiteView website
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
